Document is current
Any future updates will be listed below
-
Authors
Rancan, Chiara
Arias-Badia, Marcel https://orcid.org/0000-0003-2270-0676
Dogra, Pranay
Chen, Brandon
Aran, Dvir https://orcid.org/0000-0001-6334-5039
Yang, Hai
Luong, Diamond https://orcid.org/0000-0001-6832-5408
Ilano, Arielle
Li, Jacky
Chang, Hewitt https://orcid.org/0000-0001-9760-2304
Kwek, Serena S.
Zhang, Li
Lanier, Lewis L. https://orcid.org/0000-0003-1308-3952
Meng, Maxwell V.
Farber, Donna L. https://orcid.org/0000-0001-8236-9183
Fong, Lawrence https://orcid.org/0000-0002-6428-428X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA233100, R35CA253175, AI128949, AI106697, R21CA264381, R01LM013763-01A1, R21CA264381, R01LM013763-01A1)
Parker Institute of Cancer Immunotherapy Prostate Cancer Foundation
Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship
Parker Institute for Cancer Immunotherapy
- License Information
-
More Information
Article History
Received: 11 March 2022
Accepted: 3 February 2023
First Online: 16 March 2023
Competing interests
: L.F. has received research support from Roche/Genentech, Abbvie, Bavarian Nordic, Bristol Myers Squibb, Dendreon, Janssen, Merck and Partner Therapeutics, and has served on the scientific advisory boards of Actym, Alector, Astra Zeneca, Atreca, Bioatla, Bolt, Bristol Myers Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Merck KGA, Nutcracker, RAPT, Scribe, Senti, Sutro and Roche/Genentech. L.L.L. serves on the scientific advisory boards of Alector, Atreca, Catamaran, Dragonfly, Dren Bio, Edity, IMIDomics, Innovent, Morphosys, Nkarta, Obsidian, oNKo-innate and SBI Biotech. The remaining authors declare no competing interests.
